Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Direct Boost Adenovirus-Erasmus Medical Center-COVID-19
- Development stage
- Unknown
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Direct Boost Adenovirus-Erasmus Medical Center-COVID-19 refers to a specific intervention arm within the SWITCH ON clinical trial (NCT05471440), a multicenter, randomized, controlled trial led by the Erasmus Medical Center. This protocol involves the administration of an immediate ("direct") booster dose of a bivalent COVID-19 mRNA vaccine to healthcare workers who previously completed a primary vaccination series (priming) with an adenovirus-vectored vaccine, such as ChAdOx1 nCoV-19 (AstraZeneca) or Ad26.COV2.S (Janssen). The trial was designed to evaluate the immunogenicity and optimal timing of bivalent booster vaccinations (targeting the original SARS-CoV-2 strain and Omicron variants) in populations with different initial vaccination backgrounds to inform public health policy during the emergence of antigenically distinct variants.
- Other names
- Direct boost adenoDirect boost adeno arm
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Direct Boost Adenovirus-Erasmus Medical Center-COVID-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Direct Boost Adenovirus-Erasmus Medical Center-COVID-19.